Trial Profile

A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Casdozokitug (Primary) ; Pembrolizumab (Primary) ; Toripalimab (Primary)
Indications Carcinoma; Liver cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Coherus Biosciences; Surface Oncology

Most Recent Events

03 Dec 2024 According to a Coherus BioSciences media release, the company to report data in second to fourth line (2-4L) NSCLC in 1H 2025.
11 Sep 2024 Preliminary result data presented at the CRI-ENCI: 8th Annual International Cancer, Immunotherapy Conference.
04 Jan 2024 Planned number of patients changed from 220 to 260.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com